Earth Science Tech Inc. (OTC: ETST) is positioning itself as an exception among over-the-counter (OTC) listed companies by maintaining a strong operational and financial framework that includes hard real estate assets, vertical integration, and a debt-free balance sheet. The company's latest annual report for fiscal year 2026 shows continued revenue growth and gross profit expansion, defying the common risks associated with OTC stocks.
Investopedia identifies the lack of reliable information as a primary risk for OTC stocks, making it difficult for investors to evaluate their potential (source). However, Earth Science Tech overcomes this stigma through consistent financial disclosures and strong results. The company's fiscal year 2026 report, covering the period ending March 31, 2026, reveals revenue of $35.7 million, up from $33.1 million in fiscal 2025 (source) and $11.95 million in fiscal 2024 (source). Gross profit also rose to $25.5 million in fiscal 2026.
The company attributes this growth to strategic investments and acquisitions that have not added debt to its balance sheet. Notably, the acquisition of Avenvi created a subsidiary that develops, manages, and finances real estate, including property that houses ETST's Texas pharmacy. This vertical integration and real estate ownership provide a tangible asset base that is rare among OTC-listed firms.
Earth Science Tech's ability to achieve year-over-year growth while maintaining a robust corporate structure sets it apart in the OTC market. The company's timely filings and transparent reporting further enhance investor confidence, addressing the typical concerns about information reliability. As a result, ETST presents a unique opportunity for investors seeking exposure to a healthcare holding company with a solid operational foundation.
